Autophagy in glomerular health and disease

Seminars in Nephrology

Volumn 34, Issue 1, 2014, Pages 42-52

  Hartleben, Björn ^a,b   Wanner, Nicola ^a,c   Huber, Tobias B ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ATG5; Autophagy; Diabetic nephropathy; FSGS; Glomerulonephritis; Kidney; LC3; Lysosomal storage diseases; MTOR; Podocyte; RAPTOR

Indexed keywords

AUTOPHAGY PROTEIN 5;

AGING; AUTOPHAGY; CELL DIFFERENTIATION; CELL MATURATION; DIABETIC NEPHROPATHY; ENDOPLASMIC RETICULUM STRESS; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HOMEOSTASIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; LYSOSOME STORAGE DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ATG5; AUTOPHAGY; DIABETIC NEPHROPATHY; FSGS; GLOMERULONEPHRITIS; KIDNEY; LC3; LYSOSOMAL STORAGE DISEASES; MTOR; PODOCYTE; RAPTOR;

ANIMALS; AUTOPHAGY; CELL AGING; CELL DIFFERENTIATION; DIABETIC NEPHROPATHIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HOMEOSTASIS; HUMANS; KIDNEY GLOMERULUS; LYSOSOMAL STORAGE DISEASES; PODOCYTES;

EID: 84893378116     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.11.007     Document Type: Review

References (87)

1. Grahammer F., Schell C., Huber T.B. Molecular understanding of the slit diaphragm. Pediatr Nephrol 2013, 28:1957-1962.
2. Pavenstadt H., Kriz W., Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003, 83:253-307.
3. Lemley K.V., Lafayette R.A., Safai M., Derby G., Blouch K., Squarer A., et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002, 61:1475-1485.
4. White K.E., Bilous R.W., Marshall S.M., El Nahas M., Remuzzi G., Piras G., et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002, 51:3083-3089.
5. Wiggins R.C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007, 71:1205-1214.
6. Wharram B.L., Goyal M., Wiggins J.E., Sanden S.K., Hussain S., Filipiak W.E., et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005, 16:2941-2952.
7. Matsusaka T., Xin J., Niwa S., Kobayashi K., Akatsuka A., Hashizume H., et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005, 16:1013-1023.
8. Grahammer F., Wanner N., Huber T.B. Podocyte regeneration: who can become a podocyte?. Am J Pathol 2013, 183:333-335.
9. Wanner N, Hartleben B, Herbach N, Gödel M, Stickel N, Zeiser R, et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol. In press.
10. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
11. Yang Z., Klionsky D.J. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010, 12:814-822.
12. Ravikumar B., Sarkar S., Davies J.E., Futter M., Garcia-Arencibia M., Green-Thompson Z.W., et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010, 90:1383-1435.
13. Choi A.M., Ryter S.W., Levine B. Autophagy in human health and disease. N Engl J Med 2013, 368:651-662.
14. Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000, 19:5720-5728.
15. Klionsky D.J., Abdalla F.C., Abeliovich H., Abraham R.T., Acevedo-Arozena A., Adeli K., et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.
16. Mizushima N., Yamamoto A., Matsui M., Yoshimori T., Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004, 15:1101-1111.
17. Asanuma K., Tanida I., Shirato I., Ueno T., Takahara H., Nishitani T., et al. MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. FASEB J 2003, 17:1165-1167.
18. Hartleben B., Gödel M., Meyer-Schwesinger C., Liu S., Ulrich T., Köbler S., et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010, 120:1084-1096.
19. Huber T.B., Edelstein C.L., Hartleben B., Inoki K., Dong Z., Koya D., et al. Emerging role of autophagy in kidney function, diseases and aging. Autophagy 2012, 8:1009-1031.
20. Wiggins J.E. Aging in the glomerulus. J Gerontol A Biol Sci Med Sci 2012, 67:1358-1364.
21. McCray B.A., Taylor J.P. The role of autophagy in age-related neurodegeneration. Neurosignals 2008, 16:75-84.
22. Cuervo A.M. Autophagy and aging: keeping that old broom working. Trends Genet 2008, 24:604-612.
23. Lipinski M.M., Zheng B., Lu T., Yan Z., Py B.F., Ng A., et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci U S A 2010, 107:14164-14169.
24. Rubinsztein D.C., Marino G., Kroemer G. Autophagy and aging. Cell 2011, 146:682-695.
25. Wu L., Feng Z., Cui S., Hou K., Tang L., Zhou J., et al. Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury. PLoS One 2013, 8:e63799.
26. Papeta N., Zheng Z., Schon E.A., Brosel S., Altintas M.M., Nasr S.H., et al. Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. J Clin Invest 2010, 120:4055-4064.
27. Rotig A., Munnich A. Genetic features of mitochondrial respiratory chain disorders. J Am Soc Nephrol 2003, 14:2995-3007.
28. Yamagata K., Muro K., Usui J., Hagiwara M., Kai H., Arakawa Y., et al. Mitochondrial DNA mutations in focal segmental glomerulosclerosis lesions. J Am Soc Nephrol 2002, 13:1816-1823.
29. LeHir M., Kriz W. New insights into structural patterns encountered in glomerulosclerosis. Curr Opin Nephrol Hypertens 2007, 16:184-191.
30. D'Agati V.D. Pathobiology of focal segmental glomerulosclerosis: new developments. Curr Opin Nephrol Hypertens 2012, 21:243-250.
31. Genovese G., Friedman D.J., Ross M.D., Lecordier L., Uzureau P., Freedman B.I., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329:841-845.
32. Kopp J.B., Nelson G.W., Sampath K., Johnson R.C., Genovese G., An P., et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011, 22:2129-2137.
33. Friedman D.J., Kozlitina J., Genovese G., Jog P., Pollak M.R. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011, 22:2098-2105.
34. Papeta N., Kiryluk K., Patel A., Sterken R., Kacak N., Snyder H.J., et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011, 22:1991-1996.
35. Hu C.A., Klopfer E.I., Ray P.E. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease. FEBS Lett 2012, 586:947-955.
36. Vanhamme L., Paturiaux-Hanocq F., Poelvoorde P., Nolan D.P., Lins L., Van Den Abbeele J., et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003, 422:83-87.
37. Perez-Morga D., Vanhollebeke B., Paturiaux-Hanocq F., Nolan D.P., Lins L., Homble F., et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005, 309:469-472.
38. Zhaorigetu S., Wan G., Kaini R., Jiang Z., Hu C.A. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008, 4:1079-1082.
39. Wan G., Zhaorigetu S., Liu Z., Kaini R., Jiang Z., Hu C.A. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem 2008, 283:21540-21549.
40. Kang M.K., Kameta A., Shin K.H., Baluda M.A., Kim H.R., Park N.H. Senescence-associated genes in normal human oral keratinocytes. Exp Cell Res 2003, 287:272-281.
41. Yoon M.S., Sun Y., Arauz E., Jiang Y., Chen J. Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect. J Biol Chem 2011, 286:29568-29574.
42. Madhavan S.M., O'Toole J.F., Konieczkowski M., Ganesan S., Bruggeman L.A., Sedor J.R. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011, 22:2119-2128.
43. Cybulsky A.V. The intersecting roles of endoplasmic reticulum stress, ubiquitin- proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. Kidney Int 2013, 84:25-33.
44. Wang L., Hong Q., Lv Y., Feng Z., Zhang X., Wu L., et al. Autophagy can repair endoplasmic reticulum stress damage of the passive Heymann nephritis model as revealed by proteomics analysis. J Proteomics 2012, 75:3866-3876.
45. Sato S., Yanagihara T., Ghazizadeh M., Ishizaki M., Adachi A., Sasaki Y., et al. Correlation of autophagy type in podocytes with histopathological diagnosis of IgA nephropathy. Pathobiology 2009, 76:221-226.
46. Gödel M., Hartleben B., Herbach N., Liu S., Zschiedrich S., Lu S., et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011, 121:2197-2209.
47. Inoki K., Mori H., Wang J., Suzuki T., Hong S., Yoshida S., et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011, 121:2181-2196.
48. Inoki K., Huber T.B. Mammalian target of rapamycin signaling in the podocyte. Curr Opin Nephrol Hypertens 2012, 21:251-257.
49. Fang L., Zhou Y., Cao H., Wen P., Jiang L., He W., et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One 2013, 8:e60546.
50. Ma T., Zhu J., Chen X., Zha D., Singhal P.C., Ding G. High glucose induces autophagy in podocytes. Exp Cell Res 2013, 319:779-789.
51. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11:329-341.
52. Chen J., Chen M.X., Fogo A.B., Harris R.C., Chen J.K. mVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking. J Am Soc Nephrol 2013, 24:198-207.
53. Bechtel W., Helmstadter M., Balica J., Hartleben B., Kiefer B., Hrnjic F., et al. Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis. J Am Soc Nephrol 2013, 24:727-743.
54. Bechtel W., Helmstadter M., Balica J., Hartleben B., Schell C., Huber T.B. The class III phosphatidylinositol 3-kinase PIK3C3/VPS34 regulates endocytosis and autophagosome-autolysosome formation in podocytes. Autophagy 2013, 9:1097-1099.
55. Ludwig J., Kerscher S., Brandt U., Pfeiffer K., Getlawi F., Apps D.K., et al. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J Biol Chem 1998, 273:10939-10947.
56. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 2007, 8:917-929.
57. Riediger F., Quack I., Qadri F., Hartleben B., Park J.K., Potthoff S.A., et al. Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol 2011, 22:2193-2202.
58. Oshima Y., Kinouchi K., Ichihara A., Sakoda M., Kurauchi-Mito A., Bokuda K., et al. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol 2011, 22:2203-2212.
59. Zoncu R., Bar-Peled L., Efeyan A., Wang S., Sancak Y., Sabatini D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 2011, 334:678-683.
60. Fischer E.G., Moore M.J., Lager D.J. Fabry disease: a morphologic study of 11 cases. Mod Pathol 2006, 19:1295-1301.
61. Kobayashi H., Takahashi-Fujigasaki J., Fukuda T., Sakurai K., Shimada Y., Nomura K., et al. Pathology of the first autopsy case diagnosed as mucolipidosis type III alpha/beta suggesting autophagic dysfunction. Mol Genet Metab 2011, 102:170-175.
62. Servais A., Moriniere V., Grunfeld J.P., Noel L.H., Goujon J.M., Chadefaux-Vekemans B., et al. Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. Clin J Am Soc Nephrol 2008, 3:27-35.
63. Kashtan C.E., Nevins T.E., Posalaky Z., Vernier R.L., Fish A.J. Proteinuria in a child with sialidosis: case report and histological studies. Pediatr Nephrol 1989, 3:166-174.
64. Santoro D., Rosenbloom B.E., Cohen A.H. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy. Am J Kidney Dis 2002, 40:E4.
65. Schiffmann R. Fabry disease. Pharmacol Ther 2009, 122:65-77.
66. Chevrier M., Brakch N., Celine L., Genty D., Ramdani Y., Moll S., et al. Autophagosome maturation is impaired in Fabry disease. Autophagy 2010, 6:589-599.
67. Yu L., McPhee C.K., Zheng L., Mardones G.A., Rong Y., Peng J., et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465:942-946.
68. Liebau M.C., Braun F., Hopker K., Weitbrecht C., Bartels V., Muller R.U., et al. Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PLoS One 2013, 8:e63506.
69. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
70. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
71. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
72. Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003, 17:1829-1834.
73. Long X., Lin Y., Ortiz-Vega S., Yonezawa K., Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005, 15:702-713.
74. Fukuda A., Chowdhury M.A., Venkatareddy M.P., Wang S.Q., Nishizono R., Suzuki T., et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 2012, 23:1351-1363.
75. Narita M., Young A.R., Arakawa S., Samarajiwa S.A., Nakashima T., Yoshida S., et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 2011, 332:966-970.
76. Young A.R., Narita M. Spatio-temporal association between mTOR and autophagy during cellular senescence. Autophagy 2011, 7:1387-1388.
77. Vaughan M.R., Quaggin S.E. How do mesangial and endothelial cells form the glomerular tuft?. J Am Soc Nephrol 2008, 19:24-33.
78. Cina D.P., Onay T., Paltoo A., Li C., Maezawa Y., De Arteaga J., et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2012, 23:412-420.
79. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002, 11:1107-1117.
80. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36:585-595.
81. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006, 15:433-442.
82. Menzies F.M., Huebener J., Renna M., Bonin M., Riess O., Rubinsztein D.C. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 2010, 133:93-104.
83. Harris H., Rubinsztein D.C. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev 2012, 8:108-117.
84. Tanaka M., Machida Y., Niu S., Ikeda T., Jana N.R., Doi H., et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004, 10:148-154.
85. Sarkar S., Floto R.A., Berger Z., Imarisio S., Cordenier A., Pasco M., et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005, 170:1101-1111.
86. Sarkar S., Davies J.E., Huang Z., Tunnacliffe A., Rubinsztein DC Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007, 282:5641-5652.
87. Rose C., Menzies F.M., Renna M., Acevedo-Arozena A., Corrochano S., Sadiq O., et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet 2010, 19:2144-2153.